These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 17545406)

  • 1. Give Synagis via home care: a reply.
    Schipper JA
    Pediatrics; 2007 Jun; 119(6):1258-9; author reply 1259. PubMed ID: 17545406
    [No Abstract]   [Full Text] [Related]  

  • 2. Give Synagis via home health.
    Goldenring J
    Pediatrics; 2007 Jan; 119(1):219. PubMed ID: 17200293
    [No Abstract]   [Full Text] [Related]  

  • 3. Preventing RSV in pediatric patients: improving the outcome at home.
    Borell M; Myers J; Rineair S
    Caring; 2007 Sep; 26(9):34-7. PubMed ID: 17948847
    [No Abstract]   [Full Text] [Related]  

  • 4. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes.
    Hand IL; Noble L; Geiss D; Shotkin A
    Pediatr Infect Dis J; 2008 Feb; 27(2):175-6. PubMed ID: 18174866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors impacting compliance with palivizumab prophylaxis.
    Pignotti MS; Indolfi G; Donzelli G
    Pediatr Infect Dis J; 2004 Feb; 23(2):186-7. PubMed ID: 14872196
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prophylaxis against RS virus infection].
    Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
    Lakartidningen; 2002 Jan; 99(3):170-1. PubMed ID: 11838073
    [No Abstract]   [Full Text] [Related]  

  • 8. Health plan pharmacy director: considerations for treatment and management of RSV disease.
    Burgoyne DS
    Manag Care; 2008 Nov; 17(11 Suppl 12):17-8, discussion 18-9. PubMed ID: 19102025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
    Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
    Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
    [No Abstract]   [Full Text] [Related]  

  • 10. [Infections with RS viruses in children].
    Krankenpfl J; 2004; 42(7-10):231. PubMed ID: 15675393
    [No Abstract]   [Full Text] [Related]  

  • 11. North American synagis prophylaxis survey.
    Giusti R
    Pediatr Pulmonol; 2009 Jan; 44(1):96-8. PubMed ID: 19085922
    [No Abstract]   [Full Text] [Related]  

  • 12. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis.
    Rodríguez SP; Fariña D; Bauer G
    Pediatr Infect Dis J; 2008 Jul; 27(7):660-1. PubMed ID: 18520447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
    Krilov LR; Weiner LB; Yogev R; Fergie J; Katz BZ; Henrickson KJ; Welliver RC
    Pediatrics; 2009 Dec; 124(6):1682-4. PubMed ID: 19948634
    [No Abstract]   [Full Text] [Related]  

  • 14. CARESS: The Canadian Registry of Palivizumab.
    Taylor RS
    Pediatr Infect Dis J; 2012 Feb; 31(2):212-3; author reply 213. PubMed ID: 22252210
    [No Abstract]   [Full Text] [Related]  

  • 15. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units.
    Kurz H; Herbich K; Janata O; Sterniste W; Bauer K
    J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost and safety of multidose use of palivizumab vials.
    Gooding J; Millage A; Rye AK; Lacroix R
    Clin Pediatr (Phila); 2008 Mar; 47(2):160-3. PubMed ID: 17901213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing respiratory syncytial virus in homebound premature infants.
    Austin J
    Home Healthc Nurse; 2007; 25(7):429-32. PubMed ID: 17667001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managed care considerations: vulnerable populations and prevention strategies for respiratory syncytial virus disease.
    Peskin SR
    Manag Care; 2008 Nov; 17(11 Suppl 12):preceding table of contents. PubMed ID: 19097555
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.